(Rac) -Vazegepant-13C, d3

(Rac) -Vazegepant-13C, d3 is the C13 and deuterium labeled (Rac) -Vazegepant. Vazegepant (HY-134992) is the first intranasal CGRP receptor antagonist for the study the acute research of migraine[1][2].

Product Specifications

UNSPSC

12352005

Target

Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Others

Field of Research

Others

Solubility

10 mM in DMSO

Smiles

CC1=C2NN=CC2=CC(CC(NC(N3CCC(C4=CC5=CC=CC=C5NC4=O)CC3)=O)C(N6CCN(C7CCN([13C]([2H])([2H])[2H])CC7)CC6)=O)=C1

Molecular Formula

C35 13CH43D3N8O3

Molecular Weight

642.81

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[2]Leonard KA, et al. Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel Disease. J Med Chem. 2020 Mar 26;63 (6) :2915-2929.